drugset / Trial / NCT01018979
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
RandomizedSingle-groupOpen-labelTreatment
Summary
A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
Timeline
- Start
- 2010-02
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TG-0054 | Unknown | 2.24 mg/kg | Intravenous |
| Subject | TG-0054 | Unknown | 3.14 mg/kg | Intravenous |